Janssen had better Darzalex sales than expected in Q1
![Photo: Joost Melis / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12910530.ece/ALTERNATES/schema-16_9/doc7ff53tm74s2t0x0mdmq.jpg)
US pharmaceutical company Jansssen holds the rights for Darzalex, which was developed by Danish biotech firm Genmab and has had significantly better sales than expected in this year's first quarter.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Janssen receives new approval for Darzalex in Canada
For subscribers